The global antiviral therapy market is expanding as the rising prevalence of viral infections, technological advancements in antiviral drug development, increasing healthcare expenditure, and growing awareness and improved access to antiviral therapies accelerate market growth.

The market was valued at approximately USD 42.77 billion in 2023, about USD 45.47 billion in 2024, and is projected to reach roughly USD 74.1 billion by 2032, growing at a CAGR of approximately 6.3%. Growth is supported by increasing prevalence of viral infections, technological advancements in antiviral drug development, growing awareness and improved access to antiviral therapies, and increasing healthcare expenditure.wiseguyreports

HIV/AIDS held the largest market share in 2023 and is expected to continue to dominate the market during the forecast period. The increasing prevalence of HIV/AIDS, the availability of effective antiviral therapies, and the growing number of patients seeking treatment are driving the growth of this segment.

Nucleoside reverse transcriptase inhibitors (NRTIs) are the largest drug type segment, accounting for over 40% of the market in 2023. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are the second-largest segment, with a market share of over 30%.

Oral administration accounted for the largest market share of around 60% in 2024, owing to the ease of administration and patient compliance. The Intravenous segment is expected to witness significant growth during the forecast period due to the increasing prevalence of severe viral infections.

North America is expected to hold the largest market share in 2023, owing to the high prevalence of viral infections and the presence of a well-developed healthcare infrastructure. Key players include Gilead Sciences, AbbVie, Johnson & Johnson, Merck & Co., and Roche Holding.

Read more: Antiviral Therapy Market

People Also Ask

Q1. What is driving the antiviral therapy market?
Rising prevalence of viral infections, technological advancements in antiviral drug development, increasing healthcare expenditure, and growing awareness and improved access to antiviral therapies are major drivers.

Q2. Which infection type leads the market?
HIV/AIDS leads the market, followed by viral hepatitis and influenza.

Tags: antiviral therapy, viral infections, HIV/AIDS, antiviral drugs, infectious diseases